Examples of using Pomalidomide in English and their translations into Polish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
In monkeys, pomalidomide was evaluated in repeat-dose studies of up to 9 months in duration.
Second primary malignancies, such as non-melanoma skin cancer, have been reported in patients receiving pomalidomide see section 4.8.
In vitro binding of pomalidomide enantiomers to proteins in human plasma ranges from 12% to 44%
That pomalidomide is teratogenic in animals
If powder from pomalidomide makes contact with the skin, the skin should be washed immediately and thoroughly with soap and water.
Pomalidomide has a mean apparent volume of distribution(Vd/F) between 62 and 138 L at steady state.
The systemic exposure(AUC) of pomalidomide increases in an approximately linear
Pomalidomide must be discontinued permanently for angioedema, Grade 4 rash,
Clinically relevant drug-drug interactions are not anticipated when pomalidomide is coadministered with substrates of these pathways.
For male patients taking pomalidomide, pharmacokinetic data has demonstrated that pomalidomide is present in human semen.
If pomalidomide is taken during pregnancy, a teratogenic effect of pomalidomide in humans is expected see section 4.4.
Pomalidomide was found to be teratogenic in both rats and rabbits when administered during the period of major organogenesis.
should not receive pomalidomide.
the expected teratogenic effect of pomalidomide in humans.
carfilzomib, pomalidomide and the therapy using bone marrow auto-transplantation.
Following multiple doses, pomalidomide has an accumulation ratio of 27 to 31% on AUC.
That if his partner becomes pregnant whilst he is taking pomalidomide or shortly after he has stopped taking pomalidomide he should inform his treating doctor immediately.
Co-administration of multiple doses of up to 4 mg pomalidomide with 20 mg to 40 mg dexamethasone(a weak to moderate inducer of several CYP enzymes including CYP3A) to patients with multiple myeloma had no effect on the pharmacokinetics of pomalidomide compared with pomalidomide administered alone.
Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole,
In randomised study CC-4047-MM-003, 302 patients with relapsed and refractory multiple myeloma were exposed to 4 mg pomalidomide administered once daily for 21 days of each 28 day cycle in combination with a weekly low dose of dexamethasone.